Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody–drug conjugate

References

• Tarantino P, Pestana RC, Corti C, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022 Mar;72(2):165–182. doi: 10.3322/CAAC.21705
   PubMed Web of Science ®Google Scholar
• Ascione L, Crimini E, Trapani D, et al. Predicting response to antibody drug conjugates: a focus on antigens’ targetability. Oncologist. 2023 Nov;28(11):944–960. doi: 10.1093/ONCOLO/OYAD246
   PubMedGoogle Scholar
• Dowell JA, Korth-Bradley J, Liu H, et al. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol. 2001;41(11):1206–1214. doi: 10.1177/00912700122012751
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov;367(19):1783–1791. doi: 10.1056/NEJMOA1209124/SUPPL_FILE/NEJMOA1209124_DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update. J Clin Oncol. 2023 Aug;41(22):3867–3872. doi: 10.1200/JCO.22.02864
   PubMed Web of Science ®Google Scholar
• André F, Hee Park Y, Kim SB, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 May;401(10390):1773–1785. doi: 10.1016/S0140-6736(23)00725-0
   PubMed Web of Science ®Google Scholar
• Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021 Mar;384(12):1125–1135. doi: 10.1056/NEJMOA2035807
   PubMed Web of Science ®Google Scholar
• Moore KN, Angelergues A, Konecny GE, et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023 Dec;389(23):2162–2174. doi: 10.1056/NEJMOA2309169
   PubMed Web of Science ®Google Scholar
• Shitara K, Bang Y-J, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020 Jun;382(25):2419–2430. doi: 10.1056/NEJMOA2004413
   PubMed Web of Science ®Google Scholar
• Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 Oct;402(10411):1423–1433. doi: 10.1016/S0140-6736(23)01245-X
   PubMed Web of Science ®Google Scholar
• Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021 Apr;384(16):1529–1541. doi: 10.1056/NEJMOA2028485
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021 Aug;39(22):2474–2485. doi: 10.1200/JCO.20.03489
   PubMed Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022 Jul;387(1):9–20. doi: 10.1056/NEJMOA2203690
   PubMed Web of Science ®Google Scholar
• Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022 Jan;386(3):241–251. doi: 10.1056/NEJMOA2112431
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024 Jan;42(1):47–58. doi: 10.1200/JCO.23.02005
   PubMed Web of Science ®Google Scholar
• Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):779–789. doi: 10.1016/S1470-2045(21)00086-3
   PubMed Web of Science ®Google Scholar
• FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors | FDA. [cited 2024 Apr 11]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
   Google Scholar
• Tarantino P, Gupta H, Hughes ME, et al. Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nat Commun. 2023 Dec;14(1). doi: 10.1038/S41467-023-43324-W
   Web of Science ®Google Scholar
• Mosele F, Deluche E, Lusque A, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023 Aug;29(8):2110–2120. doi: 10.1038/S41591-023-02478-2
   PubMed Web of Science ®Google Scholar
• Tarantino P, Modi S, Tolaney SM, et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 2021 Dec;7(12):1873–1881. doi: 10.1001/JAMAONCOL.2021.3595
   PubMed Web of Science ®Google Scholar
• Powell CA, Camidge DR, Modi S, et al. 289P risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies. Ann Oncol. 2020 Sep;31:S357–S358. doi: 10.1016/J.ANNONC.2020.08.391
   Web of Science ®Google Scholar
• Izbicki G, Segel MJ, Christensen TG, et al. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(3):111–119. doi: 10.1046/J.1365-2613.2002.00220.X
   PubMed Web of Science ®Google Scholar
• Inaba K, Arimoto T, Hoya M, et al. Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer. Med Oncol. 2012 Jun;29(2):1255–1257. doi: 10.1007/S12032-011-9893-0
   PubMed Web of Science ®Google Scholar
• Jacobs C, Slade M, Lavery B. Doxorubicin and BOOP. A possible near fatal association. Clin Oncol (R Coll Radiol). 2002;14(3):262. doi: 10.1053/CLON.2002.0071
   PubMed Web of Science ®Google Scholar
• Mazzotta M, Giusti R, Iacono D, et al. Pulmonary fibrosis after pegylated liposomal doxorubicin in elderly patient with cutaneous angiosarcoma. Case Rep Oncol Med. 2016;2016:1–5. doi: 10.1155/2016/8034832
   Google Scholar
• Yoshii N, Suzuki T, Nagashima M, et al. Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports. Anticancer Drugs. 2011 Jul;22(6):563–568. doi: 10.1097/CAD.0B013E3283473F28
   PubMed Web of Science ®Google Scholar
• Willemsen AECAB, Grutters JC, Gerritsen WR, et al. mTOR inhibitor-induced interstitial lung disease in cancer patients: comprehensive review and a practical management algorithm. Int J Cancer. 2016 May;138(10):2312–2321. doi: 10.1002/IJC.29887
   PubMed Web of Science ®Google Scholar
• Shah RR. Tyrosine kinase inhibitor-induced interstitial lung disease: Clinical features, diagnostic challenges, and therapeutic dilemmas. Drug Saf. 2016 Nov;39(11):1073–1091. doi: 10.1007/S40264-016-0450-9
   PubMed Web of Science ®Google Scholar
• Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017 Aug;50(2). doi: 10.1183/13993003.00050-2017
   PubMed Web of Science ®Google Scholar
• Raschi E, Fusaroli M, Ardizzoni A, et al. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat. 2021 Feb;186(1):219–227. doi: 10.1007/S10549-020-06001-W
   PubMed Web of Science ®Google Scholar
• Tarantino P, Ricciuti B, Pradhan SM, et al. Optimizing the safety of antibody–drug conjugates for patients with solid tumours. Nat Rev Clin Oncol. 2023 Jun;20(8):558–576. doi: 10.1038/s41571-023-00783-w
   PubMed Web of Science ®Google Scholar
• Baselga J, Albanell J, Molina MA, et al. Mechanism of action of trastuzumab and scientific update. Semin Oncol. 2001 Oct;28(5 Suppl 16):4–11. doi: 10.1016/S0093-7754(01)90276-3
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016 Oct;22(20):5097–5108. doi: 10.1158/1078-0432.CCR-15-2822
   PubMed Web of Science ®Google Scholar
• Hunter FW, Barker HR, Lipert B, et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer. 2019 Dec;122(5):603–612. doi: 10.1038/s41416-019-0635-y
   PubMed Web of Science ®Google Scholar
• Giugliano F, Corti C, Tarantino P, et al. Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep. 2022 Jul;24(7):809–817. doi: 10.1007/S11912-022-01266-4
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Hagihara K, Oitate M, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039–1046. doi: 10.1111/CAS.12966
   PubMed Web of Science ®Google Scholar
• Li BT, Michelini F, Misale S, et al. Her2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov. 2020 May;10(5):674–687. doi: 10.1158/2159-8290.CD-20-0215
   PubMed Web of Science ®Google Scholar
• Doi T, Shitara K, Naito Y, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017 Nov;18(11):1512–1522. doi: 10.1016/S1470-2045(17)30604-6
   PubMed Web of Science ®Google Scholar
• Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):816–826. doi: 10.1016/S1470-2045(19)30097-X
   PubMed Web of Science ®Google Scholar
• Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):827–836. doi: 10.1016/S1470-2045(19)30088-9
   PubMed Web of Science ®Google Scholar
• Tsurutani J, Iwata H, Krop I, et al. Targeting her2 with trastuzumab deruxtecan: a dose-expansion, phase i study in multiple advanced solid tumors. Cancer Discov. 2020 May;10(5):688–701. doi: 10.1158/2159-8290.CD-19-1014
   PubMed Web of Science ®Google Scholar
• Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low–expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol. 2020;38(17):1887–1896. doi: 10.1200/JCO.19.02318
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020 Feb;382(7):610–621. doi: 10.1056/NEJMOA1914510
   PubMed Web of Science ®Google Scholar
• Saura C, Modi S, Krop I, et al. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol. 2024 Mar;35(3):302–307. doi: 10.1016/J.ANNONC.2023.12.001
   PubMed Web of Science ®Google Scholar
• Narayan P, Osgood CL, Singh H, et al. FDA approval summary: fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer. Clin Cancer Res. 2021 Aug;27(16):4478–4485. doi: 10.1158/1078-0432.CCR-20-4557
   PubMed Web of Science ®Google Scholar
• Pérez-García JM, Vaz Batista M, Cortez P, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol. 2023 Jan;25(1):157–166. doi: 10.1093/NEUONC/NOAC144
   PubMed Web of Science ®Google Scholar
• Bartsch R, Berghoff AS, Furtner J, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022 Sep;28(9):1840–1847. doi: 10.1038/S41591-022-01935-8
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023 Jan;401(10371):105–117. doi: 10.1016/S0140-6736(22)02420-5
   PubMed Web of Science ®Google Scholar
• Narayan P, Dilawari A, Osgood C, et al. US food and drug administration approval summary: fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer. J Clin Oncol. 2023 Apr;41(11):2108–2116. doi: 10.1200/JCO.22.02447
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in anti–human epidermal growth factor receptor 2 treatment–naive patients with human epidermal growth factor receptor 2–low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial. J Clin Oncol. 2023 Feb;41(4):816. doi: 10.1200/JCO.22.00575
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, di Bartolomeo M, Smyth E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023 Jul;24(7):744–756. doi: 10.1016/S1470-2045(23)00215-2
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Oh D-Y, Rha SY, et al. Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (Gc)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03. 2022 Jan;40(4_suppl):295. doi: 10.1200/JCO.2022.40.4_SUPPL.295
   Google Scholar
• Shen L, Chen P, Lu J, et al. 172P Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial. Ann Oncol. 2023 Nov;34:S1542–S1543. doi: 10.1016/j.annonc.2023.10.307
   Google Scholar
• Goto K, Goto Y, Kubo T, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol. 2023 Nov;41(31):4852–4863. doi: 10.1200/JCO.23.01361
   PubMed Web of Science ®Google Scholar
• FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer | FDA. [cited 2024 Mar 16]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung
   Google Scholar
• Raghav KPS, Siena S, Takashima A, et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. 2023 May;41(16_suppl):3501. doi: 10.1200/JCO.2023.41.16_SUPPL.3501
   Google Scholar
• Reed DR, Janeway KA, Minard CG, et al. PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: a children’s oncology group pediatric early-phase clinical trial network study. 2023 May;41(16_suppl):11527. doi: 10.1200/JCO.2023.41.16_SUPPL.11527
   Google Scholar
• Li BT, Meric-Bernstam F, Bardia A, et al. 654O efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study. Ann Oncol. 2023 Oct;34:S459–S460. doi: 10.1016/j.annonc.2023.09.1840
   Web of Science ®Google Scholar
• DiPeri TP, Evans KW, Raso MG, et al. Adavosertib enhances antitumor activity of trastuzumab deruxtecan in HER2-expressing cancers. Clin Cancer Res. 2023 Nov;29(21):OF1–OF14. doi: 10.1158/1078-0432.CCR-23-0103
   Web of Science ®Google Scholar
• Hamilton EP, Shapiro CL, Boni V, et al. 162O primary analysis from DS8201-A-U105: a 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer. Ann Oncol. 2022 May;33:S196. doi: 10.1016/j.annonc.2022.03.181
   Web of Science ®Google Scholar
• Jhaveri K, André F, Hamilton E, et al. Abstract RF02-03: Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08). Cancer Res. 2024 May;84(9_Supplement):RF02–03. doi: 10.1158/1538-7445.SABCS23-RF02-03
   Web of Science ®Google Scholar
• Hurvitz SA, Wang LS, Chan D, et al. TRIO-US B-12 TALENT: phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer. 2022 Jun;40(16_suppl):TPS623. doi: 10.1200/JCO.2022.40.16_SUPPL.TPS623
   Google Scholar
• Bardia A, Hurvitz S, Press MF, et al. Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. Cancer Res. 2023 Mar;83(5_Supplement):GS2–03. doi: 10.1158/1538-7445.SABCS22-GS2-03
   Web of Science ®Google Scholar
• Schmid P, Im S-A, Armstrong A, et al. BEGONIA: phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). 2021 May;39(15_suppl):1023. doi: 10.1200/JCO.2021.39.15_SUPPL.1023
   Google Scholar
• Schmid P, Wysocki P, Park YH, et al. Abstract PD11-08: PD11-08 Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR−), HER2-low breast cancer: updated results from BEGONIA, a phase 1b/2 study. Cancer Res. 2023 Mar;83(5_Supplement):PD11–08. doi: 10.1158/1538-7445.SABCS22-PD11-08
   Web of Science ®Google Scholar
• Cheema P, Hartl S, Koczywas M, et al. 695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON). J Immunother Cancer. 2023 Nov;11(Suppl 1):A787–A787. doi: 10.1136/JITC-2023-SITC2023.0695
   Google Scholar
• Oliveira C, Mainoli B, Gonçalo SD, et al. Immune-related serious adverse events with immune checkpoint inhibitors: systematic review and network meta-analysis. Eur J Clin Pharmacol. 2024 Feb;80(1):1–10. doi: 10.1007/S00228-024-03647-Z
   PubMedGoogle Scholar
• Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 Oct;402(10411):1423–1433. doi: 10.1016/S0140-6736(23)01245-X
   PubMed Web of Science ®Google Scholar
• Bardia A, Rugo HS, Tolaney SM, et al. Final results from the randomized phase III ASCENt clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncol. 2024 Feb;42(15):1738–1744. doi: 10.1200/JCO.23.01409
   PubMedGoogle Scholar
• Nilsson MB, Poteete A, Udagawa H, et al. Abstract 383: Trastuzumab deruxtecan resistance is associated with reduced responsiveness to topoisomerase inhibitors (payload resistance) but no reduction in sensitivity to HER2 tyrosine kinase inhibitors. Cancer Res. 2023 Apr;83(7_Supplement):383–383. doi: 10.1158/1538-7445.AM2023-383
   Web of Science ®Google Scholar
• Rolfo C, Del Re M, Russo A. Empower the potential of trastuzumab deruxtecan with novel combinations. Clin Cancer Res. 2023 Nov;29(21):4317–4319. doi: 10.1158/1078-0432.CCR-23-1700
   PubMed Web of Science ®Google Scholar